Triple Therapy Clears HIV in 8 Newborn Primates Within 3 Days of Exposure
Updated
Updated · ScienceDaily · Aug 19
Triple Therapy Clears HIV in 8 Newborn Primates Within 3 Days of Exposure
3 articles · Updated · ScienceDaily · Aug 19
Summary
Eight newborn macaques given antiretrovirals, broadly neutralizing antibodies and leronlimab within 72 hours of exposure showed complete viral clearance, with no rebound after treatment stopped.
The result stood out because each therapy had failed on its own; together, the regimen appears to suppress replication, neutralize circulating virus and block CCR5, a key entry route into immune cells.
OHSU researchers said the finding could move quickly toward human trials, likely starting with adults recently exposed to HIV before any newborn studies.
More than 120,000 babies acquire HIV each year worldwide, and the team now wants to test how long the early-treatment window remains open beyond the first three days.
If this rapid CCR5-blocking strategy cured infant monkeys, can it be adapted to eradicate established HIV reservoirs in adults?
Could a three-part antibody cocktail given hours after exposure permanently eliminate HIV in newborns before it hides?
Will the high costs and kidney risks of this triple-therapy prevent its use as an HIV cure in developing nations?
Triple-Therapy Achieves Complete HIV Clearance in Infant Macaques: The 72-Hour Window and the Challenge of Human Application
Overview
A groundbreaking study showed that giving newborn macaques a triple-therapy regimen—combining standard antiretroviral drugs, two broadly neutralizing antibodies, and the CCR5 blocker leronlimab—within 72 hours of HIV-like virus exposure completely prevented the virus from forming a permanent reservoir. This early, multi-pronged approach shut down every major pathway the virus uses to spread, keeping all treated infants free of viral rebound for over a year after stopping therapy. However, real-world challenges remain, such as the need for ultra-rapid infant diagnosis and the high cost of monoclonal antibodies, which limit access in low-resource settings. Global efforts are underway to make these therapies more affordable and accessible.